PMID- 26695551
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20221207
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Print)
IS  - 1474-0338 (Linking)
VI  - 15
IP  - 3
DP  - 2016
TI  - A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.
PG  - 393-402
LID - 10.1517/14740338.2016.1135900 [doi]
AB  - INTRODUCTION: Empagliflozin is a sodium glucose co-transporter 2 inhibitor used 
      to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) by 
      enhancing urinary glucose excretion. Empagliflozin is effective at lowering 
      glycosylated hemoglobin and was recently proven superior to placebo for reduction 
      of cardiovascular disease (CVD) risk. As with any new drug, there are safety 
      considerations that inform its potential use in patients with T2DM. AREAS 
      COVERED: Here, we evaluate the safety of empagliflozin and provide an expert 
      opinion as to its current and future role in the treatment of patients with T2DM. 
      A search of the English language literature was performed using PubMed search 
      terms: "empagliflozin", "sodium glucose cotransporter 2 inhibitors", and "drug 
      safety". Articles and bibliographies relevant to the subject were reviewed and 
      additional references known to the authors were included. EXPERT OPINION: The 
      evidence for empagliflozin is robust with regard to glycemic efficacy and safety. 
      Low risk of hypoglycemia, absence of weight gain, and demonstrated cardiovascular 
      risk reduction support its consideration as a first line medication in addition 
      to metformin for patients with T2DM and CVD. Ongoing trials will continue to 
      address the safety and efficacy of empagliflozin and expand our clinical 
      knowledge of this medication.
FAU - Neeland, Ian J
AU  - Neeland IJ
AD  - a Division of Cardiology , University of Texas Southwestern Medical Center , 
      Dallas , TX , USA.
AD  - b Department of Internal Medicine , University of Texas Southwestern Medical 
      Center , Dallas , TX , USA.
FAU - Salahuddin, Usman
AU  - Salahuddin U
AD  - b Department of Internal Medicine , University of Texas Southwestern Medical 
      Center , Dallas , TX , USA.
FAU - McGuire, Darren K
AU  - McGuire DK
AD  - a Division of Cardiology , University of Texas Southwestern Medical Center , 
      Dallas , TX , USA.
AD  - b Department of Internal Medicine , University of Texas Southwestern Medical 
      Center , Dallas , TX , USA.
AD  - c Department of Clinical Sciences , University of Texas Southwestern Medical 
      Center , Dallas , TX , USA.
LA  - eng
GR  - K23 DK106520/DK/NIDDK NIH HHS/United States
GR  - 1K23DK106520-01/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160202
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 9100L32L2N (Metformin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Benzhydryl Compounds/*adverse effects/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Glucosides/*adverse effects/pharmacology/therapeutic use
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects/pharmacology/therapeutic use
MH  - Metformin/therapeutic use
MH  - Sodium-Glucose Transporter 2 Inhibitors
PMC - PMC4890479
MID - NIHMS789453
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - drug safety
OT  - empagliflozin
OT  - sodium glucose co-transporter 2 inhibitor
EDAT- 2015/12/24 06:00
MHDA- 2016/11/01 06:00
PMCR- 2017/03/01
CRDT- 2015/12/24 06:00
PHST- 2017/03/01 00:00 [pmc-release]
PHST- 2015/12/24 06:00 [entrez]
PHST- 2015/12/24 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - 10.1517/14740338.2016.1135900 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2016;15(3):393-402. doi: 10.1517/14740338.2016.1135900. 
      Epub 2016 Feb 2.